Pharming Group N.V.

Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients suffering from rare, debilitating, and life-threatening diseases. The company's core mission is to provide solutions for underserved rare disease patient populations. Headquartered in Leiden, the Netherlands, Pharming also maintains physical locations in the USA and France.

Pharming's portfolio encompasses protein replacement therapies and precision medicines, including small molecules and biologics. Key commercialized products include RUCONEST® (conestat alfa), approved for the treatment of acute Hereditary Angioedema (HAE) attacks, and Joenja® (leniolisib), which targets Activated Phosphoinositide 3-kinase Delta (PI3Kδ) Syndrome (APDS). The company is actively engaged in expanding the indications for leniolisib to other primary immunodeficiencies (PIDs) with immune dysregulation and is advancing a pivotal stage clinical program in primary mitochondrial diseases.

Fabrice Chouraqui assumed the role of CEO and Executive Director in March 2025. Recent corporate developments include the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Joenja® in Europe and its approval in Japan for APDS in patients aged 4 years and older. Pharming reported strong financial results for the fourth quarter and full year 2025, demonstrating significant revenue growth driven by its key products. The company is strategically expanding Joenja®'s market presence globally and progressing its clinical pipeline, notably with a public cash offer in late 2024 to acquire Abliva AB, aiming to integrate KL1333 for primary mitochondrial disease into its development programs.